Choroidal melanoma

Oman Journal of Ophthalmology

Volumn 5, Issue 1, 2012, Pages 3-9

  Singh, Parul ^a   Singh, Abhishek ^a  

^a V C S G Government Medical Sciences and Research Institute   (India)

Author keywords

Choroidal; eye; melanoma; review

Indexed keywords

EID: 84865503635     PISSN: 0974620X     EISSN: 09747842     Source Type: Journal    
DOI: 10.4103/0974-620X.94718     Document Type: Review

References (62)

1. Albert DM. Principles and Practice of Ophthalmology. In: Albert, Jakobiec, editors. Ch. 258. Philadelphia, PA: W.B. Saunders Co.; 1994. p. 3197-8.
2. Ferry AP. Lesions mistaken for malignant melanoma of the posterior uvea: A clinicopathological analysis of 100 cases with ophthalmoscopically visible lesions. Arch Ophthalmol 1964;72:463-9.
3. Shields JA. Lesions simulating malignant melanoma of the posterior uvea. Arch Ophthalmol 1973;89:466-71.
4. Zimmerman LE. Bedell Lecture: Problems in the diagnosis of malignant melanoma of the choroid and ciliary body. Am J Ophthalmol 1973;75:917-9.
5. Chang M, Zimmerman LE, McLean IW. The persisting pseudomelanoma problem. Arch Ophthalmol 1984;102:726-7.
6. Shields JA, Augsburger JJ, Brown GC, Stephens RF. The differential diagnosis of posterior uveal melanoma. Ophthalmology 1980;87:518-22.
7. Char DH, Stone RD, Irvine AR, Crawford JB, Hilton GF, Lonn LI, et al. Diagnosticmodalities in choroidal melanoma. Am J Ophthalmol 1980;89:223-30.
8. Sotto J, Fraument JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: Epidemiologic aspects. J Natl Cancer Inst 1976;56:489-91.
9. Miller B, Abrahams C, Code GC, Proctor NS. Ocular malignant melanoma in South African Blacks. Br J Ophthamol 1981;65:720-2.
10. Fledelius H, Land AM. Malignant melanoma of the choroids in an 11- month- old infant. Acta Ophthamol 1975;53:160-6.
11. Jensen OA. Malignant melanoma of the uvea in Denmark 1943-1952, aclinical histopathological, and prognostic study. Acta Ophthalmol Suppl (Copenh)1963;43 Suppl 75:1-220.
12. Paul EV, Parneli BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin 1962;2:387-402.
13. Shields CL, Shields JA, Milte J, De Potter P, Sabbagh R, Menduke H. Uveal Melanoma in teenagers and children: A report of 40 cases. Ophthamology 1991;98:1662-6.
14. Raivio I. Uveal melanoma in Finland: An epidemiological, clinical, histological and prognosis study, Acta Opthalmol Suppl (Copenh)1977;133:1-64.
15. Gragoudas ES. First 1000 patients with uveal melanoma treated by proton beam irradiation. Second International Meeting on the Diagnosis and Treatment of Intraocular Tumors, in Nyon, Switzerland November 1987.
16. Mahoney MC, Burnett WS, Majerovics A, Tanenbaum H. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology1990;97:1143-7.
17. Shammas HF, Blodi FC. Prognosis factors in choriodal and ciliary body melanomas. Arch Ophthalmol 1977;95:63-9.
18. Elwood JM, Willamson C, Stapleton PJ. Malignant melanoma in relation to moles, pigmentation, and exposure to fluorescent and other lighting sources. Br J Cancer 1986;53:65-74.
19. Holman CD, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma. J Natl Cancer Ins 1984;72:257-66.
20. Ganley JP, Comstock GW. Benign nevi and malignant melanomas of the choroid. Am J Ophthalmol 1973;76:19-25.
21. Shields CL, Furuta M, Berman EL, Zahler JD, Hoberman DM, Dinh DH, et al. Choroidal nevus transformation into melanoma: Analysis of 2514 consecutive cases. Arch Ophthalmol 2009;127:981-7.
22. Lee JA, Storer BE. Excess of malignant melanomas in woman in the British Isles. Lancet 1980;2:1337-9.
23. Lee JA, Storer BE. Malignant melanoma female/male death ratios. Lancet 1981;1:1419.
24. Gallagher RP, Elwood JM, Rootman J, Spinelli JJ, Hill GB, Threlfall WJ, et al. Risk factors for ocularmelanoma: Western Canada Melanoma Study. J Natl Cancer Inst 1985;74:775-8.
25. Holly EA, Aston DA, Char DH, Kristiansen JJ, Ahn DK. Uveal melanoma in relation to ultraviolet light exposure and host factors. Cancer Res 1990;50:5773-7.
26. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1,6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:313-7.
27. Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci 2005;46:2253-7.
28. Hausler T, Stang A, Anastassiou G, Jöckel KH, Mrzyk S, Horsthemke B, et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer 2005;116:909-13.
29. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347:1222-5.
30. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19:22-8.
31. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998;83:354-9.
32. Prescher G, Bornfeld N, Becher R. Two subclones in a case of uveal melanoma: Relevance of monosomy 3 and multiplication of chromosome 8q. Cancer Genet Cytogenet 1994;77:144-6.
33. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet 1995;80:40-6.
34. Jensen OA. Malignantmelanomas of the uvea in Denmark 1943-1952. A clinical, histopathological, and prognostic Study. Acta Ophthalmol Suppl 1963;75:1-220.
35. Lishko AM, Seddon JM, Gragoudas ES, Egan KM, Glynn RJ. Evaluation of prior primary malignancy as a determinant of uveal melanoma. Ophthalmology 1989;96:1716-21.
36. Gass JD. Problems in the differential diagnosis of chorodal nevi and malignant melanomas. The XXXIII Edward Jackson Memorial Lecture. Am J Ophthalmol 1977;83:299-323.
37. Gass JD. Observation of suspected choroidal and ciliary body Melanomas forevidence of growth prior to enucleation. Ophthalmology 1980;87:523-8.
38. Mafee MF, Peyman GA, McKusick MA. Malignant uvel melanoma and similar lesions studied by computed tomography. Radiology 1985;156:403-8.
39. Peyster RG, Augsburger JJ, Shields JA, Satchell TV, Markoe AM, Clarke K, et al. Choroidal melanoma: Comparison of CT, fundoscopy and ultrasound. Radiology 1985;156:675-80.
40. Mafee MF, Peyman GA, Grisdano JF, Fletcher ME, Spigos DG, Wehrli FW, et al. Malignant melanoma and simulating lesions: MR imaging evaluation. Radiology 1986;160:773-80.
41. Kolodny NH, Gragoudas ES, D'Amico DJ, Albert DM. Magnetic resonance imaging and spectroscopy of intraocular tumors. Surv Ophthalmol 1989;33:502-14.
42. Shields JA. Current approaches to the diagnosis and management of choroidal melanomas. Surv Ophthamol 1977;21:443-63.
43. Augsburger JJ, Shield JA, Folberg R, Lang W, O'Hara BJ, Claricci JD. Fine needle biopsy in the diagnosis of intraocular cancer: Cytologic-histologic correlations. Ophthalmology 1985;92:39-49.
44. Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004;138:936-51.
45. Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand 2001;79:19-22.
46. Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. Arch Ophthalmol 1987;105:763-4.
47. Finger PT, Berson A, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: Results of a 7-year study. Ophthalmology 1999;106:606-13.
48. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:1684-93.
49. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119:969-82.
50. Gragoudas ES, Seddon J, Goitein M, Verhey L, Munzenrider J, Urie M, et al. Current results of proton beam irradiation of uveal melanomas. Ophthalmology 1985;92:284-91.
51. Woodburn R, Danis R, Timmerman R, Witt T, Ciulla T, Worth R, et al. Preliminary experience in the treatment of choroidal melanoma with gamma knife radiosurgery. J Neurosurg 2000;93:177-9.
52. Drummond M, Stoddart G, Torrence G. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1994.
53. Cruickshanks KJ, Fryback DG, Nondahl DM, Robinson N, Keesey U, Dalton DS, et al. Treatment choice and quality of life in patients with choroidal melanoma. Arch Ophthalmol 1999;117:461-7.
54. Melia M, Moy CS, Reynolds SM, Hayman JA, Murray TG, Hovland KR, et al. Quality of life after iodine 125 brachytherapy vsenucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol 2006;124:226-38.
55. Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma risk factors and influence on survival probability. Ophthalmology 2008;115:1778-85.
56. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, et al. Cytogenetics of uveal melanoma: A 7-year clinical experience. Ophthalmology 2007;114:1925-31.
57. Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000;107:1443-9.
58. Willson JK, Albert DM, Diener-West M. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. Arch Ophthalmol 2001;119:670-6.
59. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Screening for metastasis from choroidal melanoma. The Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004;22:2438-44.
60. Bedician AY. Metastatic uveal melanoma therapy: Current options. Int Ophthalmol Clin 2006;46:151-66.
61. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma. Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005;123:1639-43.
62. Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol 2010; 128:871-5.